[Retracted] To Systematically Evaluate and Analyze the Efficacy and Safety of Transcatheter Arterial Chemoembolization (TACE) in the Treatment of Primary Liver Cancer

Table 1

Basic clinical features of 12 literature were included in our study.

Study	Age	Gender (man)	Disease types	Experimental group (N)	Control group (N)	NOS score	Research type
Borgheresi A 2020	53.71 ± 12.2	41.25	Advanced liver cancer	98	70	8	RCT
Görgec B 2020	65.65 ± 13.4	69.12	Advanced liver cancer	88	60	7	RCT
Yamada R 2019	53.12 ± 14.5	45.72	Advanced liver cancer	120	110	8	RCT
Van Rosmalen 2019	67.15 ± 14.5	44.12	Advanced liver cancer	68	60	8	RCT
Nurili F 2021	52.85 ± 11.4	51.89	Advanced liver cancer	60	75	8	RCT
Newgard BJ 2019	64.36 ± 10.2	63.45	Advanced liver cancer	56	67	7	RCT
Yarmohammadi 2018	62.62 ± 12.2	78.10	Advanced liver cancer	80	77	9	RCT
Kouri BE 2018	62.61 ± 13.0	48.75	Advanced liver cancer	81	60	9	RCT
Lewis AL 2018	57.25 ± 14.5	59.23	Advanced liver cancer	43	58	7	RCT
Ronald J 2018	66.22 ± 15.2	56.22	Advanced liver cancer	60	72	8	RCT
Furumaya A 2019	71.35 ± 11.1	53.16	Advanced liver cancer	110	102	8	RCT
Franken LC 2020	57.25 ± 16.0	66.34	Advanced liver cancer	90	79	8	RCT